Although measurement of CCL5 expression in BALF cells is inadequate for distinguishing IPF from other ILDs, such data provide new evidence that CCL5 is involved in pulmonary fibrotic disease and that modulation of CCL5 is a potential therapeutic strategy for IPF. The gene discussed is CCL5; the disease is idiopathic pulmonary fibrosis.